In the last trading session, 6.43 million shares of the Calidi Biotherapeutics Inc (AMEX:CLDI) were traded, and its beta was 0.93. Most recently the company’s share price was $0.34, and it changed around $0.1 or 39.47% from the last close, which brings the market valuation of the company to $11.56M. CLDI currently trades at a discount to its 52-week high of $3.89, offering almost -1044.12% off that amount. The share price’s 52-week low was $0.20, which indicates that the current value has risen by an impressive 41.18% since then. We note from Calidi Biotherapeutics Inc’s average daily trading volume that its 10-day average is 4.31 million shares, with the 3-month average coming to 793.00K.
Calidi Biotherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended CLDI as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
Instantly CLDI has showed a green trend with a performance of 39.47% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently down -82.72% year-to-date, but still up 45.65% over the last five days. On the other hand, Calidi Biotherapeutics Inc (AMEX:CLDI) is -6.06% down in the 30-day period. We can see from the shorts that 0.37 million shares have been sold at a short interest cover period of 0.74 day(s).
The consensus price target as assigned by Wall Street analysts is $5.5, which translates to bulls needing to increase their stock price by 93.82% from its current value. Analyst projections state that CLDI is forecast to be at a low of $2 and a high of $9.
Calidi Biotherapeutics Inc earnings are expected to increase by 84.85% in 2025, but the outlook is positive 53.95% per year for the next five years.
CLDI Dividends
Calidi Biotherapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-14.
Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.81% of Calidi Biotherapeutics Inc shares, and 17.24% of them are in the hands of institutional investors. The stock currently has a share float of 18.50%. Calidi Biotherapeutics Inc stock is held by 39.0 institutions, with RED WAVE INVESTMENTS LLC being the largest institutional investor. By 2024-06-30, it held 1.1723% of the shares, which is about 0.62 million shares worth $0.12 million.
CPR INVESTMENTS INC., with 1.0511% or 0.56 million shares worth $0.11 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 353.38 shares worth $0.12 million, making up 0.97% of all outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held roughly 141.47 shares worth around $47392.0, which represents about 0.39% of the total shares outstanding.
